|
Index of reports
> Disability (14)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Epirubicin disability. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Epirubicin side effects in female
Reported by a individual with unspecified qualification from Denmark on 2012-06-15
Patient: female
Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Epirubicin
Indication: Breast Cancer
Start date: 2010-12-07
Cyclophosphamide
Indication: Breast Cancer
Start date: 2010-12-07
Taxotere
Indication: Breast Cancer
Start date: 2010-12-07
Other drugs received by patient: Clemastine Fumarate
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-05-21
Patient: female
Reactions: Maternal Exposure During Pregnancy, Cardiomyopathy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Epirubicin
Indication: Breast Cancer
Possible Epirubicin side effects in female
Reported by a consumer/non-health professional from South Africa on 2012-04-16
Patient: female, weighing 56.0 kg (123.2 pounds)
Reactions: Injection Site Extravasation, Alopecia, Thrombophlebitis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Taxotere
Indication: Chemotherapy
Start date: 2008-08-27
End date: 2008-10-27
Fluorouracil
Indication: Chemotherapy
Start date: 2008-07-11
End date: 2008-07-31
Epirubicin
Indication: Chemotherapy
Start date: 2008-07-11
End date: 2008-07-31
Cyclophosphamide
Indication: Breast Cancer
Start date: 2008-07-11
End date: 2008-07-31
Possible Epirubicin side effects in 53 year old female
Reported by a lawyer from Denmark on 2012-03-29
Patient: 53 year old female
Reactions: Thrombosis, Pain in Extremity, Thrombectomy, LEG Amputation
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Taxotere
Indication: Breast Cancer
Start date: 2010-12-07
Cyclophosphamide
Indication: Breast Cancer
Start date: 2010-12-07
Epirubicin
Indication: Breast Cancer
Start date: 2010-12-07
Other drugs received by patient: Clemastine
Possible Epirubicin side effects in female
Reported by a lawyer from Denmark on 2012-03-27
Patient: female
Reactions: Thrombosis, Pain in Extremity, LEG Amputation, Thrombectomy
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Taxotere
Indication: Breast Cancer
Start date: 2010-12-07
Epirubicin
Indication: Breast Cancer
Start date: 2010-12-07
Cyclophosphamide
Indication: Breast Cancer
Start date: 2010-12-07
Other drugs received by patient: Clemastine Fumarate
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-03-20
Patient: female
Reactions: Blood Iron Decreased, Alopecia, Hair Growth Abnormal, Hair Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Dosage: unk
Administration route: Oral
Start date: 2011-04-01
Epirubicin
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Fluorouracil
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Cyclophosphamide
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Taxotere
Dosage: unk
Start date: 2010-12-16
End date: 2011-01-27
Possible Epirubicin side effects in female
Reported by a lawyer from Germany on 2012-03-05
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Epirubicin
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Cyclophosphamide
End date: 2009-10-01
Other drugs received by patient: Doxycycline; Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin
Possible Epirubicin side effects in female
Reported by a lawyer from Germany on 2012-03-02
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Docetaxel
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Docetaxel
Dosage: unk
Start date: 2009-08-25
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Cyclophosphamide
End date: 2009-10-01
Other drugs received by patient: Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin; Doxycycline
Possible Epirubicin side effects in 55 year old female
Reported by a physician from Germany on 2011-11-25
Patient: 55 year old female, weighing 75.0 kg (165.0 pounds)
Reactions: Endometrial Cancer
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Fluorouracil
Epirubicin
Cyclophosphamide
Trastuzumab
Start date: 2010-10-27
Docetaxel
Possible Epirubicin side effects in 55 year old female
Reported by a physician from Germany on 2011-11-22
Patient: 55 year old female, weighing 75.0 kg (165.0 pounds)
Reactions: Endometrial Cancer
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Fluorouracil
Docetaxel
Cyclophosphamide
Trastuzumab
Start date: 2010-10-27
Epirubicin
Possible Epirubicin side effects in female
Reported by a consumer/non-health professional from Denmark on 2011-11-22
Patient: female, weighing 53.0 kg (116.6 pounds)
Reactions: Pain, Paralysis, Myalgia, Fatigue, Coordination Abnormal, Peripheral Motor Neuropathy, Back Pain, Condition Aggravated, Hypoaesthesia, Paraesthesia, Dysgeusia, Burning Sensation, Arthralgia, Sensory Disturbance, Asthenia, Neuritis, Walking Disability, Disability
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Epirubicin
Indication: Breast Cancer
Start date: 2009-10-19
Epirubicin
Start date: 2009-11-01
Taxotere
Start date: 2009-09-28
End date: 2009-09-28
Taxotere
Indication: Breast Cancer
Start date: 2009-09-28
End date: 2009-09-28
Other drugs received by patient: Cyclophosphamide; Cyclophosphamide; Neulasta
Possible Epirubicin side effects in female
Reported by a pharmacist from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Docetaxel
Dosage: unk
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Docetaxel
Dosage: unk
End date: 2009-09-15
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
Start date: 2009-08-25
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Other drugs received by patient: Radiation; Aspirin; Factor Xiii (Fibrin Stabilising Factor); Doxycycline
Possible Epirubicin side effects in female
Reported by a pharmacist from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Dosage: unk
End date: 2009-10-13
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Docetaxel
Dosage: unk
Start date: 2009-08-04
Other drugs received by patient: Factor Xiii (Fibrin Stabilising Factor); Doxycycline; Aspirin; Radiation
Possible Epirubicin side effects in female
Reported by a lawyer from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Dosage: unk
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Other drugs received by patient: Aspirin; Doxycycline; Factor Xiii (Fibrin Stabilising Factor); Radiation
|
